Disruptive nanotechnology solution for the treatment of aggressive cancers with a high incidence worldwide through the intracellular release of monoclonal antibodies in tumour and metastatic cells. This spin-off of the University of Santiago de Compostela has emerged from the laboratory of Professor María José Alonso, where the patented MPN Technology™ platform has been developed. MPN Technology enables progress in the use of biological drugs in the personalised treatment of cancer to treat targets that were previously unapproachable pharmacologically.
“BioIncubaTech – High Technology Incubator for the promotion of innovation and transfer of biotechnology in the field of health and food technologies to micro and SME’s” is an operation co-financed by the European Regional Development Fund – ERDF within the Pluri-regional Operational Programme of Spain ERDF 2014-2020 OP Project “High Technology Incubators for the promotion of innovation and transfer of technology to micro and SME’s”.
A WAY OF MAKING EUROPE